Sumatriptan transmucosal - BDSI

Drug Profile

Sumatriptan transmucosal - BDSI

Alternative Names: Transmucosal sumatriptan - BDSI

Latest Information Update: 20 Nov 2014

Price : $50

At a glance

  • Originator QLT USA
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 17 Aug 2006 Discontinued - Preclinical for Migraine in USA (Transmucosal)
  • 22 Nov 2004 Atrix Laboratories has been acquired by QLT
  • 03 Jul 2002 Preclinical trials in Migraine in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top